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mouse mimic limitations of joint function and
locomotion in patients with Hurler syndrome
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Abstract
Background: Mucopolysaccharidosis type I (MPS I) is caused by the deficiency of alpha-L-iduronidase (IDUA), which
is involved in the degradation of glycosaminoglycans (GAGs), such as heparan sulfate and dermatan sulfate in the
lysosome. It has been reported that joint symptoms are almost universal in MPS I patients, and even in the case of
attenuated disease, they are the first symptom that brings a child to medical attention. However, functional tests
and biological markers have not been published for the evaluation of the limitations in joint and locomotion in
animal model-mimicking MPS.
Methods: We generated IDUA knockout (KO) mice to observe whether they present impairment of joint function.
KO mice were characterized phenotypically and tested dual-energy X-ray absorptiometry analysis (DEXA), open-field,
rotarod, and grip strength.
Results: The IDUA KO mice, generated by disruption between exon 6 and exon 9, exhibited clinical and laboratory
findings, such as high urinary GAGs excretion, GAGs accumulation in various tissues, and significantly increased
bone mineral density (BMD) in both female and male mice in the DEXA of the femur and whole bone. Remarkably,
we observed a decrease in grasp function, decreased performance in the rotarod test, and hypo-activity in the
open-field test, which mimic the limitations of joint mobility and decreased motor performance in the 6-min walk
test in patients with MPS I.
Conclusions: We generated a new IDUA KO mouse, tested open field, rotarod and grip strength and demonstrated
decrease in grip strength, decreased performance and hypo-activity, which may be useful for investigating therapeutic
approaches, and studying the pathogenesis of joint and locomotion symptoms in MPS I.
Keywords: IDUA, IDUA KO mice, BMD, Rotarod test, Open-field test
Background
Mucopolysaccharidosis type I (MPS I), known as Hurler
syndrome [OMIM, #607014], is caused by a deficiency
of IDUA lysosomal enzyme, and is inherited as auto-
somal recessive disease. This enzyme is involved in
glycosaminoglycans (GAGs)’ metabolic pathway, and its
deficiency causes GAGs accumulation in the lysosomes.
MPS I has three subtypes depending on phenotypic
involvement: MPS I-H (Hurler), the severe type; MPS I-
S (Scheie), the mild type; and MPS I-HS (Hurler–Scheie)
are intermediated in phenotypic expression [1]. MPS I-H
is characterized by impaired cognitive development,
progressive coarsening of the facial features, hepatosple-
nomegaly, respiratory failure, cardiac valve dysfunction,
recurrent otitis media, corneal clouding, musculoskeletal
manifestations, such as joint stiffness and contractures,
and dysostosis multiplex. The symptoms arise after birth
and progress rapidly [2]. MPS I-S, in which the symp-
toms occur later and progress slowly, is the most attenu-
ated form of MPS I. While some individuals with this
form have no neurologic involvement and psychomotor
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development may be normal in early childhood, learning
disabilities can be present. Hearing loss and cardiac
valvular disease are common. Death, typically caused by
cardiorespiratory failure, usually occurs within the first
ten years of life [2, 3]. MPS I-HS manifests in infancy
with intermediate severity. The somatic symptoms re-
duce life expectancy to the second or third decade of
life. Generally, there is no cognitive impairment, al-
though some patients may exhibit mild learning diffi-
culties [4].
Among its symptoms, musculoskeletal manifestations
are an important clue for the diagnosis of MPS I. As the
disease evolves, carpal tunnel syndrome, stiffening of the
interphalangeal joint, hook finger, and gripped hand are
common and impair hand function [5]. In particular,
MPS has been known to be the most common cause of
carpal tunnel syndrome in children [6]. Carpal tunnel
syndrome is caused by the thickening of the flexor reti-
naculum and the tissues around the tendon sheaths.
Additionally, surgical release of the tendons can improve
hand function [7].
Some MPS I animal models have been developed or
naturally occurred previously in felines [8, 9], canines
[10–12], and mice [13–16]. The canine model was used
in the efficacy test of enzyme replacement therapy (ERT)
[10, 17, 18]. Two MPS I-H mouse models have been
generated by gene disruption in exon 6 [13, 14], and
they were shown to have similar phenotypes with those
of MPS I-H patients. Another model was generated by
knock-in that carries a nonsense mutation, IDUA-
W392X, being introduced into exon 9, and they found
correlations with other MPS I-H animal model charac-
teristics, including decreased enzyme activity, the accu-
mulation of GAGs in the urine, and lysosomal storage in
many kinds of cells [15].
In addition to these animal models, in the present
study we generated another MPS I-H mouse model with
large deletion from exons 6 to 9 in the IDUA gene. We
found that our IDUA knockout (KO) mice exhibited
findings that are the same as those reported before, such
as increased urinary and tissue GAGs and thick bone
[13–16]. Moreover, we present detailed behavior func-
tions of the mice, especially in relation to joint and loco-
motion function, which can be used in evaluating the
efficacy of the therapeutic modalities in MPS I. Thus, we
expect that the IDUA KO mouse model presented here




This study was reviewed and approved by the Institu-
tional Animal Care and Use Committee (IACUC) of the
Samsung Biomedical Research Institute (SBRI). SBRI is
an accredited facility by the Association for Assessment
and Accreditation of Laboratory Animal Care International
(AAALAC International) and abides by the Institute of
Laboratory Animal Resources (ILAR) guidelines.
Generation of IDUA KO mice
The IDUA KO mouse model of Hurler syndrome was
generated by replacing a part of the IDUA gene located
on chromosome 5 (NC_0000701.5) in mice with the
neomycin resistance gene. OSDupDel.Neo vector was
used as expression vector (Open Biosystems, Alabama,
USA), and the KO construct included intron 1 to a part
of exon 6 of the IDUA gene (2534 bp) for the left arm, a
region from a part of exon 9 to the outside of exon 14
for the right arm (7112 bp), and the neomycin resistance
gene (1300 bp). pOSDupDel.Neo-IDUA construct was
transfected into embryonic stem cells, and the positive
cell clones were selected by Southern blotting and
microinjected into C57BL/6 blastocysts. Targeted disrup-
tion of the mouse IDUA locus was performed by hom-
ologous recombination with the neomycin resistance
gene. IDUA embryonic stem (ES) cell clones and F1 off-
spring were analyzed after EcoRI digestion of genomic
DNA by Southern blotting with a 5’-probe consisting of
896 bp (Fig. 1a). The genomic DNA band size was 10
Kbp for the wild type and 4.2 Kbp for IDUA KO mice
bred with a wild-type C57BL/6 strain. All offspring were
genotyped using the PCR of tail genomic DNA. To per-
form the PCR screening of IDUA KO mice, four kinds
of primers were used: TTCCAGACCCTGTTGGGTG
GGC (forward) and AGCTCTCCAAGGTTGTGGCA
GG (reverse) for the wild type (500 bp) and GAT CG
GCCATTGAACAAGAT (forward) and ATACTTTCTC
GGCAGGAGCA (reverse) for the knockout (345 bp).
The offspring included wild-type (IDUA+/+) and hetero-
zygous (IDUA+/−) mice.
Urinary and tissue GAGs assays
Urine was collected and tissue extracts were prepared by
sonication in phosphate buffer saline from the wild type
(n = 4) and IDUA KO (n = 4). The tissue extracts were
prepared by sonication in phosphate buffer saline. Ex-
tracts were centrifuged at 20,000 g for 30 min, and
supernatants were collected. GAGs concentrations in
urine and tissue were quantified via colorimetric assay
(Kamiya Biomedical Co., USA) according to the manu-
facturer’s instructions, and absorbance was measured
at 620 nm using a chondroitin 6-sulfate standard
curve. Tissue GAG contents were normalized to the
total protein concentration measured using a BCA
assay (Pierce, Rockford, IL, USA), and urinary GAG
excretion was normalized to creatinine by creatinine
assay (Sigma-Aldrich, St Louis, MO, USA).
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Histological analysis of liver and kidney
After the perfusion of the mice with ice-cold normal
saline, their tissues were collected and fixed with 4 %
paraformaldehyde overnight at 4 °C. The next day, the
tissues were embedded in paraffin (Sigma-Aldrich) after
dehydration through a 70–100 % ethanol gradient. Fi-
nally, the paraffin blocks were cut to a thickness of
4 μm. Hematoxylin-eosin staining of sections was per-
formed according to standard protocols. Images of each
section were captured with a digital camera magnifier
using a Nikon ECLIPS 80i FL Upright Microscope
(Nikon Melville, NY) and were saved as JPEG files.
X-ray test
Skeletal abnormalities of the mice were examined with
an X-ray test using the MX-20 cabinet system (Faxitron,
Tucson, AZ, USA) as follows: The mice were anesthe-
tized with intraperitoneal-injected 12.5 mg/kg of Zoletil
along with 2.5 mg/kg of Xylazine and further sedated in
a 5 % isoflurane chamber for 20 s. The sedated mice
were placed on an X-ray tray and posed for lateral, dor-
sal–ventral, forelimb, and hindlimb views. X-ray films
were taken in each at 26 kV for 16 s. The lateral view
was imaged at 1x and 3x magnitude for whole body gen-
erals and skull details, respectively; the dorsal–ventral
view was imaged at 1x and 4x magnitude for whole body
generals and skull details, respectively; and the forelimb
and hindlimb views were imaged at 5x and 3x magni-
tude, respectively. In the forelimb and hindlimb images,
the tibia length was measured and the foot bones were
analyzed for digit numbers and dysmorphology.
Dual-energy X-ray Absorptiometry test (DEXA)
DEXA testing was conducted to determine the fat
contents and bone mineral density of the mouse sub-
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Fig. 1 Generation of IDUA knockout mouse and gross photos of external morphology. a The wild-type allele (upper) of the IDUA gene consists
of 14 exons, while the targeted allele (lower) includes exon 1 to a part of exon 6 and a part of exon 9 to 14. The IDUA KO construct (lower) was
integrated into the mouse IDUA gene locus by homologous recombination. b Genomic DNA obtained from 11 F1 offspring mice were digested
EcoRI. Southern blotting analysis was performed with 5’-probe (896 bp, hybridized to the left arm region of both alleles). Wild-type mice showed
10 Kbp, and the heterozygous type showed 10 and 4.2 Kbp. c PCR analysis of the IDUA gene was performed in tail genomic DNA to confirm the
expected deletion of the IDUA gene. d The IDUA KO mouse showed a flattened facial profile, more blunt nose, less prominent eyes, rough fur,
and thickening of the digits
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anesthetized as in the X-ray test, positioned for the
dorsal–ventral view, including the tail on a DEXA tray,
and irradiated four times by X-ray with lower energy
(40 kV) and four times with high energy (70 kV) and
averaged. Bone mineral density (BMD) and contents
(BMC) were analyzed in the whole-skeleton, and
femur area and fat content were calculated in the
whole-body excluding the head area. The DEXA
equipment (Lunar PIXImus) was calibrated with a
plastic phantom mouse provided by the manufacturer
at the 1320 threshold.
Open-field test
The explorative activity of the mice was assessed by
open-field tests as follows. The mice (WT; n = 5, KO;
n = 6) were allowed to explore an open-top arena
(44.5 cm x 44.5 cm) sided with opaque walls (15.0-
cm height) and video-recorded for 20 min. The re-
corded videos were analyzed for exploration distance,
moving speed, resting time, the retention time of each
subject mouse in the central (zone 3) and peripheral
zones (zone 1 and 2), and the number of entries in each
zone. The central zone was defined as the enclosed area
(31.0 cm x 31.0 cm) at the center of the arena, and the
peripheral zone was the rest of the arena, excluding the
central zone.
Rotarod test
The motor balance and learning of the mice was
assessed by a rotarod test as follows. The mice (WT; n =
5, KO; n = 6) were habituated on a rod rotating at 4 rpm
for 1 min and subsequently tested at 4–40 rpm for
5 min and recorded for latency at 4–40 rpm. The test
was repeated three times with 10-min intervals for re-
covery for one set of experiments, and three sets of ex-
periments were conducted for three consecutive days
with 24-h intervals between each set.
Grip strength test
The grip strength of mouse paws was measured using a
grip strength meter (Bioseb, Vitrolles, France) as follows:
The mice (WT; n = 5, KO; n = 6) were allowed to grip
the metal grid of the grip strength meter with their front
paws or all four paws while their tails were suspended
perpendicular to the grid and subsequently dragged by
pulling their tails parallel to the grid until their front
paws reached the end of the grid. The test was repeated
three times without intervals between each test, and the
grip strength data were recorded in g-force units.
Statistical analysis
All results are expressed as the mean ± SEM. Statistical
significance was determined for the compared measure-
ments via a two-tailed t-test, followed by Sigmaplot 12.5
(Systat Software, Inc.); p-values of < 0.05 were considered
significant.
Results
Targeting of IDUA gene and generation of IDUA KO mice
For the targeting of the IDUA gene and generation of
IDUA KO mice, ES cells were electroporated with line-
arized pOSDupDel.Neo-IDUA KO vector, and then
plated on fibroblast feeder layers. The ES cells were
treated with geneticin (neomycin analog) to select cells
that had incorporated the targeting construct. ES cell
clones that survived drug selection were screened for
homologous recombination events using Southern blot
analysis. In the process of constructing the pOSDupDel.-
Neo-IDUA KO vector, an exogenous Xho I restriction
site and Sal I restriction site were introduced at the 5’
end of the Neo cassette and the 3’ end of the Neo cas-
sette, respectively (Fig. 1a). Therefore, ES cell genomic
DNA was digested with EcoRI and DNA blots hybridized
with a probe corresponding to an IDUA gene region lo-
cated 5’ and 3’ to the integration site of the construct.
With this strategy, the native allele and a mutant allele
produced by homologous recombination were indicated.
A single clone of the ES cells that had undergone hom-
ologous recombination was microinjected into blasto-
cysts, and 10 chimeric mice were generated. Six of the
chimeras demonstrated 90 % chimerism by color. Five
chimeric males transmitted the mutated allele through
the germline. Heterozygote offspring were identified by
both PCR and the Southern analysis of the genomic
DNA (Fig. 1b, c). Heterozygotes exhibited a grossly
normal phenotype and normal fertility. Genotyping 124
offspring from the heterozygote crosses revealed the ex-
pected Mendelian ratios (+/+ 37/124, 29.8 %; +/− 54/
124, 43.5 % and −/− 33/124, 26.6 %), indicating no sig-
nificant effect on embryo development. The IDUA KO
mice showed coarse facial features and sporadic alope-
cia, broadened paws, and thickening of the digits and
palmar regions in the phenotypic analysis (Fig. 1d).
Urinary GAGs excretion, tissue GAGs accumulation, and
histological analysis
Since IDUA plays a role in the degradation of GAGs,
such as heparan sulfate and dermatan sulfate, the pri-
mary biomarker in the knockout mice is GAGs accumu-
lation. To determine the elevation of GAGs excretion,
samples were collected from the wild type and knockout
at 9 weeks and 19 weeks for urine and at 22 weeks for
tissue. The urine GAGs level was normalized to urine
creatinine. The IDUA KO mice showed significantly in-
creased urine GAGs levels at 9 weeks of age (p < 0.01)
and 19 weeks of age (p < 0.001) (Fig. 2a). In addition, the
GAGs levels were measured in the brain, heart, liver,
lung, kidney, and spleen of wild-type and knockout mice
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and normalized to total protein (Fig. 2b). In all tissues,
GAGs accumulation showed increased level ranges from
1.8- to 90-fold. The histological analysis also showed
that many GAGs had accumulated in the lysosomes of
the liver and kidney in IDUA KO mice (Fig. 2c). Further-
more, growth and developmental retardation of these
organs was detected in IDUA KO mice. In the case of
the liver, the following pathological characteristics
were shown. Lysosome-laden Kupffer cells were read-
ily found at 4 weeks of age with very little evidence of
significant hepatocyte storage. By 10 weeks of age, fur-
ther progression of GAG accumulation within the
reticulo-endothelial system had occurred, and there
was evidence of significant hepatocyte vacuolation. At
this age, 20 to 30 % of the cytoplasm of the hepato-
cytes appeared to be taken up by lysosomes, compared
with very few discernible lysosomes within normal
liver samples, and vacuolization of the cells occurred
in the kidney also at 10 weeks of age.
DEXA assessment and radiographs
Sixteen-week-old male and female IDUA KO mice were
collected and scanned for bone density by dual-energy
X-ray absorptiometry (DEXA). Femur and whole-bone
mineral density (BMD), and bone mineral content (BMC)
were assessed (Table 1). Male and female IDUA KO mice
had significantly greater femur BMDs compared with
age-matched wild-type mice (0.074 ± 0.002 vs. 0.064 ±
0.001, p < 0.05 and 0.068 ± 0.002 vs. 0.059 ± 0.002, p <
0.01, respectively). In the whole-body analysis, BMD,
BMC, and bone area also increased overall in the
IDUA KO mice compared with the wild-type mice.
However, the tibia length in IDUA KO mice tended to
be shorter than that of the age-matched wild type, but
it did not reach statistical significance.
Behavioral analysis
We quantified the grip strength, latency on rotarod, and






Fig. 2 Glycosaminoglycan (GAG) excretion in the urine and accumulation of GAGs in several organs in IDUA KO mice. a The urinary excretion of
GAGs of 9-week-old (n = 4) and 19-week-old (n = 4) KO mice were significantly higher than those of wild-type mice at the same ages (n = 5). The
data were presented as mean ± SEM. b GAGs accumulated in the tissues of IDUA KO mice were higher than those of wild-type mice. Asterisk (*)
indicates a statistically significant difference (p < 0.05). c Histological analysis of kidney and liver tissues: By 10 weeks of age, GAGs storage within
the reticulo-endothelial system had occurred and hepatocyte vacuoles were noted. Arrow shows vacuoles
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As shown in Fig. 3a and b, both the forelimbs and hin-
dlimbs were significantly impaired in the IDUA KO mice
(p < 0.005, respectively). Defects in motor function were
confirmed on the rotarod and in the open field, in which
there was a significant decrease in rearing activity. Dur-
ing the training day, the IDUA KO mice showed the
shortest latencies to fall compared with their control
littermates (Fig. 3c). The IDUA KO mice spent less time
in the peripheral zones compared with the wild-type
mice (Fig. 3d, e).
In the open-field test, the KO mice showed less ex-
ploratory behavior. They spent significantly less time ex-
ploring (Fig. 3d), and the moving speed was significantly
decreased in the KO mice, especially in the peripheral
Table 1 Summary of parameters and statistics for bone mineral analysis by DEXA and tibia length by X-ray in the IDUA KO mice at
the age of 16 weeks (mean ± SEM)
Parameters Male Female
WT (n = 4) KO (n = 4) WT (n = 5) KO (n = 6)
Femur BMD (g/cm2) 0.064 ± 0.001 0.074 ± 0.002**** 0.059 ± 0.002 0.068 ± 0.002***
BMC (g) 0.031 ± 0.001 0.037 ± 0.0002* 0.03 ± 0.0008 0.038 ± 0.001****
Bone area (cm2) 0.48 ± 0.007 0.505 ± 0.006**** 0.502 ± 0.018 0.553 ± 0.006
Body BMD (g/cm2) 0.047 ± 0.001 0.053 ± 0.0005** 0.046 ± 0.0004 0.051 ± 0.0006*
BMC (g) 0.547 ± 0.032 0.755 ± 0.027** 0.0541 ± 0.014 0.700 ± 0.017*
Bone area (cm2) 11.703 ± 0.388 14.233 ± 0.503*** 11.806 ± 0.348 13.787 ± 0.237*
Tibia length (mm) 18.043 ± 0.239 17.555 ± 0.147 18.396 ± 0.110 18.099 ± 0.105
*p < 0.001, **p < 0.005, ***p < 0.01, ****p < 0.05
BMD: Bone mineral density; BMC: Bone mineral content
D E
A B C
Fig. 3 Behavior analysis including grip strength, rotarod, and open-field tests in 9-week-old female IDUA KO mice (n = 5). a, b IDUA KO mice had
reduced forelimb strength and reduced forelimb combined with hindlimb grip strength. The data were analyzed by normalizing the mean to
body weight. Each mouse was tested three times. c Rotarod performance was analyzed daily for 3 days. Although no significant difference was
observed, there was a decrease of latency to fall tendency in IDUA KO mice. d, e In the open-field test, IDUA KO mice traveled shorter distances
and more slowly compared with wild-type mice. Zones 1 and 2 are located at peripheral area, and zone 3 represents central zone
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zone (Fig. 3e). Thus, all of these results suggest that the
IDUA KO mouse has defects in motor function, which
affect both the quality and quantity of activity.
Statistical analysis
The statistical analysis for all experiments was per-
formed using the two-sample t-test. P-values of < 0.05
were considered significant. If equal variance failed, the
Mann–Whitney rank sum test was used. The error bars
refer to mean ± SEM.
Discussion
In this study, we observed a decrease in grip function,
decreased performance in the rotarod test, and hypo-
activity in the open-field test in the IDUA knockout
mouse, which mimic the limitations of joint mobility
and decreased motor performance in 6-min walk tests in
patients with MPS I. Furthermore, these behavioral tests
and parameters can be used in evaluating the efficacy of
the therapeutic modalities in MPS I. Decrease in grip
function in mice is consistent with the severe limitation
of the joint function caused by claw-hand deformity
and/or carpal tunnel syndrome in patients with MPS
I. Decreased performance in the rotarod test, which
reflects motor balance and learning, and hypo-activity
in the open-field test are also consistent with de-
creased performance in 6-min walk tests, which is the
gold standard test for the evaluation of the efficacy of
therapy in patients with MPS I. Dr. Muenzer reported
that the skeletal changes of MPS I patients result in
profound loss of joint range of motion and restricted
mobility. The hands and wrists of patients show decreased
range of wrist motion, stiffening of the IP joint, and
curved finger [19].
Animal models are required for therapeutic drug de-
velopment; therefore, the MPS I-type murine model has
been generated and reported in addition to naturally
occurring MPS I disease-type animals [8–16] (Table 2).
Here, we report the generation of an IDUA knockout
mouse produced by gene targeting the disruption of the
murine IDUA gene using homologous recombination;
our IDUA KO mice have a large deletion from exons 6
and 9. This mouse model showed increased urinary
GAGs excretion and tissue GAGs accumulation (Fig. 2),
similar to the previously described results (Table 2). It
has been known that GAGs accumulate in all the organs
because Hurler syndrome is a systemic disorder caused by
genetic mutation [20]. There are several reports showing
the accumulation of GAGs in organs [21–24]. It has been
well known that the liver and kidney are organs represen-
tative of the accumulation of quite a large amount of
GAGs [20]. Moreover, these organs showed the dramatic
effect of the diminution of GAGs after enzyme replace-
ment therapy in patients with Hurler syndrome and an
animal study [17, 18, 25, 26].
We observed significant differences in the bone min-
eral density and bone mineral content of the femur and
whole bone in DEXA analysis. The IDUA KO mice
showed increased BMD in both the males and females
compared with the wild-type mice (Table 1).
It is well known that MPS I patients have skeletal abnor-
malities (termed dysostosis multiplex), including enlarged
skull, short and thick thorax, brachydactyly, and irregular
carpal bones in the hands [5, 19, 27–29]. The clavicles are
short, thickened, and irregular. The long bones are short
with wide shafts. The endochondral growth plates are
thickened and distorted. Typically, the pelvis is poorly
formed. The femoral heads are small, and the coxa valga
is common. Severe joint deformity and stiffness are
common [30]. Although dysostosis multiplex was hard
to determine in the KO mouse because of the tiny size
of its individual bones, IDUA KO mice tend to have
broad and short bone in radiograph (Additional file 1:
Figure S1). These findings coincide with reported MPS
I mouse model [14–16].
Some previous studies showed that BMD increased
in the mouse model of MPS I, like the clinical features
in human MPS I patients [31, 32]. Wang reported
that BMD was increased in 35-week-old mice [15].
Garcia-Rivera et al. also described eight-month-old
NOD-SCID-MPS-I (IDUAnull: MPS-I) mice with thick-
ening of the zygomatic arch of the skull [13]. In the
present study, the IDUA KO mice showed these find-
ings at 16 weeks, which is consistent with previous
Table 2 Hurler syndrome mouse model in the literature and
the present study
Deleted locus Properties Reference
Exon 6 • Targeted disruption [14], Clarke K
• No detectable IDUA enzyme
activity
• Increased urinary GAGs
• Flattened facial profile
• Thickening of the digits
Exon 6 • Targeted disruption [13], Ohmi K
• No phenotype data




• No detectable IDUA enzyme
activity
• Increased GAGs in the urine
and tissues
From a part of exon
6 to a part of exon 9
• Targeted disruption This study
• Increased urine GAGs excretion
• Increased BMD and BMC
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reports [15, 24, 25], but the change was noted at a
younger age.
MPS I-H patients show developmental delay and a
decrease in intellectual capacity. Neuropsychological
manifestations may arise from primary GAGs accumu-
lation in the central nervous system or be caused by
deposits in adjacent structures, such as the meninges
and bone structures [33]. Besides central nervous sys-
tem dysfunction, peripheral nerve abnormalities and
muscle contracture may account for some of the man-
ifestations, such as carpal tunnel syndrome, observed
in patients with MPS I-H. Initial subtle clinical signs
of carpal tunnel syndrome in MPS I patients include
alterations in grasp patterns, increasing difficulty with
fine motor tasks, and withdrawal of the hands from
the touch of others [34]. In this study, we admit that
the joint and locomotion disturbance in the KO mouse
may have partly resulted from the dysfunction of the
central and peripheral nervous system.
Lastly, we want to mention that the open-field test
measures the activity level of the animal [35]. The
open-field box consisted of a black square box, in
which each animal was placed for ten minutes. The
overall distance traveled by the IDUA KO mice was
significantly shorter than that traveled by the wild-
type or heterozygous mice, which also showed a
slower moving speed. The IDUA KO mice had a
shorter traveling distance and decreased moving dis-
tance (Fig. 3d, e), suggesting that IDUA KO mice are
hypoactive, and this hypo-activity can be quantitated
in open-field testing. The severe developmental effects
in children with MPS I are also associated with placid
rather than aggressive behavior [33]. Animal models
are helpful to understand the disease biology and
pathophysiology, but the behavioral aspects are much
more complex and species-specific. Despite these limi-
tations, combining these tests in a murine model will
be a valuable tool for the development of therapeutics
and the study of pathologic behavior for patients with
MPS type I.
Conclusions
We generated a new IDUA KO mouse, tested open field,
rotarod, and grip strength and demonstrated a decrease in
grip strength, decreased performance, and hypo-activity,
which may be useful for investigating therapeutic ap-
proaches and studying the pathogenesis of joint and
locomotion symptoms in MPS I.
Additional file
Additional file 1: Figure S1. Radiograph of IDUA KO and wild type
mice. Arrows show the area where thickness of the bone is evident.
(PPTX 440 kb)
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